Kymera Therapeutics To Present New Clinical Data From The Phase 1 Trial Of STAT3 Degrader KT-333 At The ASH Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Kymera Therapeutics (NASDAQ:KYMR) announced new clinical data from the Phase 1 trial of STAT3 degrader KT-333, highlighting safety, pharmacokinetics, pharmacodynamics, and clinical responses. The data will be presented at the ASH 65th Annual Meeting and Exposition in December 2023. The abstract reported Phase 1 data from 21 patients, with one partial response reported after two cycles in a CTCL patient and stable disease reported after two cycles in three solid tumor patients. No dose limiting toxicities or serious adverse events were reported.
November 02, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kymera Therapeutics' new clinical data from the Phase 1 trial of STAT3 degrader KT-333 shows promising results, with early signs of antitumor activity and no serious adverse events reported.
The announcement of positive clinical trial results typically has a positive impact on a biopharmaceutical company's stock. In this case, Kymera Therapeutics' Phase 1 trial of STAT3 degrader KT-333 shows promising results, with early signs of antitumor activity and no serious adverse events reported. This could increase investor confidence in the company and its product, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100